JP6573895B2 - 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 - Google Patents

治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 Download PDF

Info

Publication number
JP6573895B2
JP6573895B2 JP2016551767A JP2016551767A JP6573895B2 JP 6573895 B2 JP6573895 B2 JP 6573895B2 JP 2016551767 A JP2016551767 A JP 2016551767A JP 2016551767 A JP2016551767 A JP 2016551767A JP 6573895 B2 JP6573895 B2 JP 6573895B2
Authority
JP
Japan
Prior art keywords
acid
nanoparticles
weight percent
phase
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016551767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505800A (ja
JP2017505800A5 (enExample
Inventor
フィグエイレド，マリア
ピーク，エリック
デウィット，デイビッド
ジーン オーブン，クリスティナ バン
ジーン オーブン，クリスティナ バン
トロイアーノ，グレッグ
ライト，ジェームズ
ソン，ヤン−ホ
ワン，ホン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2017505800A publication Critical patent/JP2017505800A/ja
Publication of JP2017505800A5 publication Critical patent/JP2017505800A5/ja
Application granted granted Critical
Publication of JP6573895B2 publication Critical patent/JP6573895B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2016551767A 2014-02-13 2015-02-13 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 Expired - Fee Related JP6573895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939363P 2014-02-13 2014-02-13
US61/939,363 2014-02-13
PCT/US2015/015887 WO2015123562A1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (3)

Publication Number Publication Date
JP2017505800A JP2017505800A (ja) 2017-02-23
JP2017505800A5 JP2017505800A5 (enExample) 2018-03-22
JP6573895B2 true JP6573895B2 (ja) 2019-09-11

Family

ID=52595474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551767A Expired - Fee Related JP6573895B2 (ja) 2014-02-13 2015-02-13 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法

Country Status (11)

Country Link
US (2) US10080723B2 (enExample)
EP (1) EP3104838B1 (enExample)
JP (1) JP6573895B2 (enExample)
CA (1) CA2939261C (enExample)
DK (1) DK3104838T3 (enExample)
ES (1) ES2770733T3 (enExample)
HU (1) HUE047934T2 (enExample)
PL (1) PL3104838T3 (enExample)
PT (1) PT3104838T (enExample)
SI (1) SI3104838T1 (enExample)
WO (1) WO2015123562A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3104838T3 (da) 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
BR112018003110A2 (pt) * 2015-08-21 2018-09-25 Pfizer nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
EP3432864B1 (en) * 2016-03-22 2020-05-06 Pfizer Inc Process for preparing therapeutic nanoparticles
WO2018208993A1 (en) * 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) * 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
EP3784705A4 (en) * 2018-04-23 2022-03-02 Graybug Vision, Inc. IMPROVED CONTINUOUS PRODUCTION OF MICROPARTICLES
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20260199517A1 (en) * 2022-11-18 2026-07-16 Haima Therapeutics, Llc Lyophilization buffers for peptide-decorated liposomes
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법
US20260108582A1 (en) * 2024-10-23 2026-04-23 Finitus, LLC Compositions and methods for intranasal delivery of carnosine for treatment of neurodegenerative diseases and disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869884B2 (en) * 2002-08-22 2005-03-22 Chartered Semiconductor Manufacturing Ltd. Process to reduce substrate effects by forming channels under inductor devices and around analog blocks
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
BR112015005878A2 (pt) * 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
HUE034490T2 (en) * 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
DK3104838T3 (da) 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
ES2770733T3 (es) 2020-07-02
US20170042828A1 (en) 2017-02-16
US10080723B2 (en) 2018-09-25
EP3104838A1 (en) 2016-12-21
PT3104838T (pt) 2020-02-14
PL3104838T3 (pl) 2020-07-13
JP2017505800A (ja) 2017-02-23
EP3104838B1 (en) 2020-01-01
US20190111004A1 (en) 2019-04-18
SI3104838T1 (sl) 2020-04-30
CA2939261A1 (en) 2015-08-20
DK3104838T3 (da) 2020-02-24
WO2015123562A1 (en) 2015-08-20
US10583092B2 (en) 2020-03-10
HUE047934T2 (hu) 2020-05-28
CA2939261C (en) 2023-03-28

Similar Documents

Publication Publication Date Title
US10583092B2 (en) Therapeutic nanoparticles comprising a protonatable nitrogen therapeutic agent and methods of making and using same
JP2018184459A (ja) 治療剤を含む治療用ナノ粒子とその製造方法および使用方法
US10577351B2 (en) Therapeutic polymeric nanoparticles and methods of making and using same
TWI693937B (zh) 包含治療劑之治療性奈米顆粒及其製造及使用方法
KR20150056618A (ko) 치료 나노입자의 제조 방법
US20180311177A1 (en) Therapeutic Nanoparticles Comprising A Therapeutic Agent and Methods of Making and Using Same
JP2017513950A (ja) Ｋ−ｒａｓ変異を有するがんを処置するためのドセタキセルを含むナノ粒子
US10022360B2 (en) Polymeric nanoparticles and methods of making and using same
JP2017514893A (ja) 治療用ナノ粒子でがんを処置する方法
HK1254347B (en) Therapeutic polymeric nanoparticles and methods of making and using same

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181105

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20181109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190814

R150 Certificate of patent or registration of utility model

Ref document number: 6573895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees